Semper Paratus Acquisition (TVGN) News Today $0.90 +0.03 (+3.61%) Closing price 04:00 PM EasternExtended Trading$0.90 -0.01 (-0.61%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVGN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase PositionsAugust 8 at 11:37 AM | globenewswire.comTevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth StrategyAugust 7 at 9:00 AM | globenewswire.comTevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase PositionsAugust 6 at 3:59 PM | globenewswire.comTevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on OncologyAugust 5 at 2:32 PM | globenewswire.comSemper Paratus Acquisition (NASDAQ:TVGN) Given Buy Rating at D. Boral CapitalAugust 5 at 8:35 AM | marketbeat.comSemper Paratus Acquisition (NASDAQ:TVGN) Given "Buy" Rating at D. Boral CapitalAugust 5 at 3:01 AM | americanbankingnews.comSemper Paratus Acquisition Corporation (NASDAQ:TVGN) Sees Significant Increase in Short InterestAugust 2, 2025 | marketbeat.comTevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to StockholdersAugust 1, 2025 | globenewswire.comTevogen Bio to Accept $1 Million Additional Grant Funding for AI ExpansionAugust 1, 2025 | globenewswire.comTevogen Highlights 74% Insider Ownership, Reinforcing Long-Term VisionJuly 30, 2025 | globenewswire.comTevogen.AI Applauds U.S. Government's AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in HealthcareJuly 28, 2025 | globenewswire.comSemper Paratus Acquisition (NASDAQ:TVGN) Shares Down 2.7% - Should You Sell?July 24, 2025 | marketbeat.comTevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active PeptidesJuly 18, 2025 | globenewswire.comTevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing FacilityJuly 17, 2025 | globenewswire.comTevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha LaunchJuly 16, 2025 | globenewswire.comTevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development CostsJuly 14, 2025 | globenewswire.comTevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate InnovationJuly 10, 2025 | globenewswire.comTevogen Bio Holdings Inc News (TVGN) - Investing.comJuly 8, 2025 | investing.comSemper Paratus Acquisition (NASDAQ:TVGN) Shares Down 2.4% - Here's WhyJuly 2, 2025 | marketbeat.comTevogen CEO Contributes to Build-Out and First-Year Operations of New HeadquartersJune 30, 2025 | globenewswire.comSemper Paratus Acquisition's (TVGN) "Buy" Rating Reaffirmed at D. Boral CapitalJune 18, 2025 | marketbeat.comTevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target DiscoveryJune 18, 2025 | globenewswire.comTevogen Bio Expands Headquarters To Support Growth In AI And Generics & Biosimilars InitiativesJune 12, 2025 | nasdaq.comTevogen Bio Expands Headquarters to Enhance R&D and Operational Efficiency with Support from MicrosoftJune 10, 2025 | nasdaq.comTevogen Bio (NASDAQ:TVGN) Given "Buy" Rating at D. Boral CapitalJune 10, 2025 | marketbeat.comRyan H. Saadi Sells 1,438,206 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) StockJune 10, 2025 | insidertrades.comInsider Selling: Tevogen Bio Holdings Inc. (NASDAQ:TVGN) CEO Sells 1,438,206 Shares of StockJune 9, 2025 | marketbeat.comTevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars InitiativesJune 9, 2025 | globenewswire.comtevogen bio expands office lease in new jersey with key amendmentJune 5, 2025 | investing.comTevogen Bio breidt kantoorruimte uit in New Jersey met belangrijke wijzigingJune 4, 2025 | nl.investing.comTevogen Bio breidt AI-initiatief uit voor ontwikkeling immunotherapieJune 1, 2025 | nl.investing.comTevogen Bio Holdings Inc. (NASDAQ:TVGN) Sees Significant Drop in Short InterestJune 1, 2025 | marketbeat.comTevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks PartnershipsMay 30, 2025 | globenewswire.comTevogen Bio (NASDAQ:TVGN) Earns "Buy" Rating from D. Boral CapitalMay 28, 2025 | marketbeat.comTevogen Peports Plans to Increase the Target Population for TVGN 489May 26, 2025 | msn.comTevogen expands target for COVID treatment to seniorsMay 24, 2025 | investing.comTevogen Bio Inc: Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to ...May 24, 2025 | finanznachrichten.deTevogen breidt doelgroep voor COVID-behandeling uit naar 65-plussersMay 23, 2025 | nl.investing.comTevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to FollowMay 23, 2025 | globenewswire.comTevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual MeetingMay 22, 2025 | globenewswire.comD. Boral Capital Reiterates "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)May 14, 2025 | marketbeat.comTevogen Bio Positions Itself as a Leader in Cost-Efficient Healthcare Amid Global Pharmaceutical CompetitionMay 13, 2025 | nasdaq.comTevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient InnovationMay 12, 2025 | globenewswire.comTevogen Bio Holdings Inc. Announces Letter of Intent with CD8 Technology Services for Cell Therapy Manufacturing FacilityMay 2, 2025 | nasdaq.comTevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder InterestMay 2, 2025 | globenewswire.comD. Boral Capital Reaffirms "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)May 1, 2025 | marketbeat.comCD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million CommitmentApril 30, 2025 | uk.finance.yahoo.comCD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million CommitmentApril 30, 2025 | globenewswire.comTevogen Bio shares surge on revenue forecastApril 29, 2025 | investing.comTevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage AccountsApril 29, 2025 | globenewswire.com Get Semper Paratus Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter. Email Address TVGN Media Mentions By Week TVGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TVGN News Sentiment▼0.130.38▲Average Medical News Sentiment TVGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TVGN Articles This Week▼94▲TVGN Articles Average Week Get Semper Paratus Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CorMedix News Today Oculis News Today GH Research News Today Tango Therapeutics News Today Mind Medicine (MindMed) News Today Maze Therapeutics News Today Niagen Bioscience News Today Upstream Bio News Today Day One Biopharmaceuticals News Today KalVista Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TVGN) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Semper Paratus Acquisition Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Semper Paratus Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.